The global market of anti-malarial drugs is riding on the back of the research and developmental activities for anti-malaria drugs due to the growing number of malaria cases around the world. These factors have driven the market players to work effortlessly for the elimination of the malaria which has further increased the demand for efficient disease management strategies such as prevention control, resources for early diagnosis and efficient anti-malaria drugs. Moreover, increasing awareness about early symptoms, constant monitoring and easy availability of therapeutics is predicted to benefit the expansion of the global anti-malaria drugs market in upcoming years.
The global anti-malaria drugs market accounted for USD 742.5 Million in 2016 and is predicted to reach remarkable market valuation of USD 1,049.5 Million by the end of 2027. Further, the global anti-malaria drugs market is estimated to witness CAGR of 3.2% during the forecast period i.e. 2018-2027.
Geographically, the global anti-malaria drugs market is segmented by regions into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa. Among these regions, Middle East & Africa accounted for more than 50% of the market share in overall anti-malaria drugs market during 2016 and is predicted to continue with its positive growth owing to the growing rate of malaria cases and lack of resources to control the local transmission of the disease in this region. Further, Asia Pacific anti-malaria drugs market is predicted to account for second highest market share with India & China as the major contributors behind the growth of the market in this region.
The global anti-malaria drugs market is divided by anti-malaria activity into tissue schizonticides, blood schizonticides, gametocytocides, sporontocides & others, out of which, the gametocytocides segment with 60.3% share in 2016 is believed to occupy the largest market of anti-malaria drugs across the globe owing to their ability to destroy the sexual forms of the parasite in the blood and thereby prevent transmission of the infection to the mosquito. Further, blood schizonticides segment is expected to achieve Y-o-Y growth rate of 3.4% in 2027.
The Report titled “Global Anti-Malaria Drugs Market Outlook: Industry Demand Analysis & Opportunity Assessment 2016–2027” also includes some prominent market analyzing parameters such as industry growth drivers, restraints, supply and demand risk, market attractiveness, year-on-year (Y-O-Y) growth comparisons, market share comparisons, BPS analysis, SWOT analysis and Porter’s five force model.
This report also studies existing competitive scenario of some of the key players of the global anti-malaria drugs market which includes profiling of Mylan Labs, Cipla Ltd., GlaxoSmithKline Plc., Novartis AG, Roche Inc., Bayer AG, Lincoln Pharmaceuticals Ltd., Strides Pharma Science Limited, Glenmark Pharmaceutical and Alliance Pharmaceuticals Limited.
The profiling enfolds key information of the companies which comprises of business overview, products and services, key financials and recent news and developments. Conclusively, the report titled “Global Anti-Malaria Drugs Market Outlook 2027”, analyses the overall anti-malaria drugs industry to help new entrants to understand the details of the market. In addition to that, this report also guides existing players looking for expansion and major investors looking for investment in the global anti-malaria drugs market in the near future.